WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259), announced a partnership with Korean biotech AbTis to accelerate the development and manufacturing of antibody drug conjugates (ADCs). The collaboration will leverage WuXi XDC’s integrated services and AbTis’s proprietary ADC platform technology.
Partnership Details
AbTis will utilize WuXi XDC’s comprehensive services, including linker and payload manufacturing, ADC conjugation process development, formulation, and drug product manufacturing. WuXi XDC’s facilities, located within a two-hour drive of each other, enable seamless end-to-end development.
AbTis’s ADC Platform
AbTis specializes in ADC platform technology with proprietary patents. Its site-specific linker technology enhances ADC safety and efficacy without requiring antibody mutation, applicable to native, commercial, or novel antibodies.
WuXi XDC’s Capabilities
WuXi XDC offers end-to-end contract research, development, and manufacturing for bioconjugates, including ADCs. As of April 30, 2022, WuXi XDC had 240+ projects in development, with 26 IND filings and 8 in Phase II/III trials. The company has reduced ADC development timelines to 15 months or less.-Fineline Info & Tech
